hPTH-1-37 (Hemopratide for psoriasis and oesteoporosis) - Haemopep Pharma GmbH
Hemoparatide (hPTH-1-37) is being tested for metabolic, bone and skin diseases after completion of Phase 1. At present a study on its efficacy with psoriasis is currently being performed. The project is run by Haemopep Pharma GmbH, an active subsidiary of Pharis Biotec GmbH since December 2006.
Hemoparatide (hPTH-1-37) is being tested for metabolic, bone and skin diseases after completion of Phase 1. At present a study on its efficacy with psoriasis is currently being performed. The project is run by Haemopep Pharma GmbH, an active subsidiary of Pharis Biotec GmbH since December 2006.
